中醫名著
0
Quality Score
Niche
中醫名著
Low confidence
✍️ bumetric analysis
“
中醫名著 is an Android app from Stoxline in the Books & Reference category, currently rated — across few ratings. Initial signal reads as mostly critical sentiment so far: users flag rough edges and unmet expectations.
Quality Score is 0: Niche (micro-niche or pre-traction stage). For a Books & Reference app, that means micro-niche or pre-traction stage. The full BU Investment Matrix below scores 8 dimensions including monetisation, growth, and operational risk.
Track changes month-over-month in the Performance section below: live snapshot history and revenue forecast included.
💰 Monthly revenue · now vs forecast
● Right now
$500
per month
→
12-mo forecast
$437 – $1575
per month
→
24-mo forecast
$405 – $3644
per month
INDIE tier
💡 Grow this revenue
Free AI audit of this app’s store listing
- Title & subtitle keyword fit
- Description hook & conversion structure
- Screenshots, ratings, reviews strategy
Typical impact: +2-5× organic installs
📊 Performance Tracking LIVE
Loading…
Rating
—
Reviews
—
Forecast Revenue / mo
—
Snapshots tracked
0
since first record
ONE-TIME · BUILD
💰 Estimated build cost
$75K
↳ What it cost to build · not monthly revenue
Likely range $55K – $100K
$25K · MVP floor
$100K · indie scale
$500K+ · studio build
📈
Slow ROI — current MRR is well below build cost
Synthetic estimate. Inputs: category complexity, file size, screen count, monetization layer, platform reach, age × team-size proxy. Calibrated against 2024-2026 indie-agency rate surveys. Full math + source list on /methodology.
Where the money goes
| 🧱 MVP baseline (design + 1-store ship) | +$28K |
| 📱 5 unique screens × $4.5K | +$22K |
| ⚙ Books & Reference complexity ×0.95 | $-2525 |
| 🌐 Cross-platform reach (iOS + Android) | +$26K |
Total estimate
$75K
🔬
How we forecast this revenue
LOW CONFIDENCEBaseline
$500/mo · ML-estimated from 234 triggers
Growth rate
+6.0% MoM · INDIE tier baseline (compound monthly)
Direction
Headwinds: rating drift may slow acquisition
6 months
$426 – $993
12 months
$437 – $1.6K
24 months
$405 – $3.6K
Compound growth at +6.0% MoM (tier baseline for INDIE). Range widens with horizon — typical noise band ±40% at 6mo.. Ranges widen with horizon — distant futures carry more uncertainty.
📊
BU Investment Matrix
Pre-traction · 37/100INDIE TIERlimited signalRevenue Strength
2.7
Product Quality
0.0
Market Position
0.0
Growth Velocity
5.0
Defensibility
7.4
Operational Safety
7.0
Founder Strength
6.2
Monetization Maturity
1.0
- 💰 Revenue: Marginal — $200 - $1250/mo · INDIE tier · medium confidence, trajectory unclear.
- ⭐ Quality: None★ across 0 reviews — weak — significant quality concerns.
- 📍 Market: Not yet charting in any of the 9 monitored markets.
- 📈 Growth: ⚠ last update 539d ago — possibly dormant.
- ⚠️ Risk: Moderate — dormant (539d since update).
🎯 For competitors: Mixed picture. Worth competing if you have a clear UX or pricing edge — otherwise crowded segment.
💵 For acquirers: Estimated asking range 18-32× monthly = $9K-$16K. Portfolio play ($4K/mo combined) commands premium.
Composite of 8 dimensions computed deterministically from public signals — no LLM, every score traces back to a measurable input. Default weights shown; "compete" / "acquire" / "invest" lenses re-weight without re-fetching.
Range:
💰 Forecast Revenue / mo
MODELRevenue forecast computed from BU's 234 trigger model on each snapshot. Calibrated against ground-truth from 58 verified-revenue apps.
📈 Reviews Growth
LIVECumulative review count from first BU snapshot. Each point = a tracked update.
⭐ Rating Trend
LIVEAverage rating evolution. Updates with each new review batch.
Profile & Insights
Everything we know — and don't — about this app and its company.
Identification
- App name
- 中醫名著
- Developer
- Stoxline
- Bundle ID
- com.stoxline.zhongyifanti
- App Store URL
- Open in App Store
- Category
- Books & Reference
- Content rating
- Not found
- Languages
- Not found
Company
- Website
- www.stoxline.com
- Tagline
- Not found
- Description
- Not found
- Founded
- Not found
- HQ / Address
- Not found
- Employees
- Not found
- Logo
- Not found
Revenue
- Verified revenue / mo
- Not found
- AI revenue estimate / mo
- Not found
- AI annual estimate
- Not found
- ML model estimate / mo
- $223/mo
- Top-grossing rank
- Not found
- All-time revenue
- Not found
- Pricing
- Not found
Founder
Founder data not yet collected for this app.
Funding
Funding data not yet collected for this app.
Press & Links
Press & Links data not yet collected for this app.
Contacts & Socials
Contacts & Socials data not yet collected for this app.
Profile is built from iTunes Lookup + developer site scrape + ML revenue model. Empty fields show "Not found" — additional sources (Crunchbase, X, IndieHackers, Acquire.com) coming.
📝 About this app
中醫名著 （繁體） 包括，四大經典《黃帝內經》《難經》《傷寒雜病論》《溫病條辨》，四小經典《湯頭歌訣》《藥性歌括四百味》《瀕湖脈學》《醫學三字經》，外加《本草綱目》《金匱要略》《神農本草經》三本中醫名著。
《黃帝內經》分《靈樞》、《素問》兩部分，是中國最早的醫學典籍。《黃帝內經》在黃老道家理論上建立了中醫學上的“陰陽五行學說”、“藏象學說”、“病因學說”、“養生學說”、“藥物治療學說”、“經絡治療學說”等學說[1] 。從整體觀上來論述醫學，呈現了自然——生物——心理——社會“整體醫學模式”，是中國影響最大的一部醫學著作，被稱為醫之始祖。
《難經》是戰國時期 出版的圖書，作者是扁鵲 ，原名《黃帝八十一難經》，古代中醫學著作之一，傳說為戰國時期秦越人（扁鵲）所作。本書以問答解釋疑難的形式編撰而成，共討論了81個問題，故又稱《八十一難》，全書所述以基礎理論為主，還分析了一些病證。其中一至二十二難為脈學，二十三至二十九難為經絡，三十至四十七難為臟腑，四十八至六十一難為疾病，六十二至六十八為腧穴，六十九至八十一難為針法。
《傷寒雜病論》是中國傳統醫學著作之一，作者是張仲景。傷寒雜病論系統地分析了傷寒的原因、癥狀、發展階段和處理方法，創造性地確立了對傷寒病的“六經分類”的辨證施治原則，奠定了理、法、方、藥的理論基礎。… View full description on the official store →
《黃帝內經》分《靈樞》、《素問》兩部分，是中國最早的醫學典籍。《黃帝內經》在黃老道家理論上建立了中醫學上的“陰陽五行學說”、“藏象學說”、“病因學說”、“養生學說”、“藥物治療學說”、“經絡治療學說”等學說[1] 。從整體觀上來論述醫學，呈現了自然——生物——心理——社會“整體醫學模式”，是中國影響最大的一部醫學著作，被稱為醫之始祖。
《難經》是戰國時期 出版的圖書，作者是扁鵲 ，原名《黃帝八十一難經》，古代中醫學著作之一，傳說為戰國時期秦越人（扁鵲）所作。本書以問答解釋疑難的形式編撰而成，共討論了81個問題，故又稱《八十一難》，全書所述以基礎理論為主，還分析了一些病證。其中一至二十二難為脈學，二十三至二十九難為經絡，三十至四十七難為臟腑，四十八至六十一難為疾病，六十二至六十八為腧穴，六十九至八十一難為針法。
《傷寒雜病論》是中國傳統醫學著作之一，作者是張仲景。傷寒雜病論系統地分析了傷寒的原因、癥狀、發展階段和處理方法，創造性地確立了對傷寒病的“六經分類”的辨證施治原則，奠定了理、法、方、藥的理論基礎。… View full description on the official store →
App Specs
🔐 Own this app? Claim & verify MRR →🔖 v2.0.8🔄 updated 0d ago📂 Books & Reference💰 Free📺 Ad-supported
🔔
Track this app’s revenue
FREEGet an email when revenue moves by your threshold. No spam, unsubscribe in one click.
📝 Description
95
BU Score · Transcendent
More by Stoxline
View all →📦 Portfolio summaryINDIE studio
35apps·$4K/mocombined
✓ Diversified — top app contributes 6%; risk spread across portfolio
About this analysis
Why low confidence: only 0 ratings · no founder-verified revenue (model estimate only) · revenue figure is directional only.
📌 Final verdict — read this before you trust the numbers above
中醫名著 is a very early-stage Android app in the books & reference space with weak public traction — only 0 ratings, no founder-verified MRR, and not ranked in any monitored grossing chart. The app appears to be monetised, but public signals are too sparse for a precise revenue estimate.
Bottom line: treat all revenue, audience and acquisition-value numbers on this page as directional only — not founder-verified facts.
❓ Frequently Asked Questions
3 answers · auto-generated from this app's public dataHow much does 中醫名著 make per month?▴
Low-confidence model estimate. 中醫名著 has only 0 App Store ratings, so our revenue model has very little signal to work with — treat the ~$222/mo figure as directional only, not a verified MRR. No founder-verified revenue data is available for this app. See methodology for the formula and confidence bands.
What apps are like 中醫名著?▴
Browse the full Books & Reference category catalog to find similar apps with revenue, build cost, audience and tech stack data. Each /p/{slug} page also shows a Compare side-by-side widget with three peer apps from the same niche.
Who makes 中醫名著?▴
中醫名著 is published by Stoxline on the Google Play Store. See the full publisher portfolio (other apps by the same developer) via the More by developer block on the product page above.